Aird F, Kandela I, Mantis C, Reproducibility Project: Cancer Biology. 2017. Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. eLife 6:e21253. doi: 10.7554/eLife.21253.
Published 19, January 2017
This is a corrigendum for Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
The calculation of variance in the meta-analysis of the overall survival distributions for mice treated with (+)-JQ1 vs. mice treated with vehicle control (Figure 4B) is incorrect. Subsequently, the effect size and the associated p value of the meta-analysis are incorrect. The effect size (Hazard Ratio) for this comparison should be HR = 9.16 95% CI [1.39, 60.54] (instead of the reported HR = 13.12 95% CI [1.79, 96.02]) resulting in a p value of p = 0.0215 (instead of the reported p = 0.0112).
The language surrounding this comparison in the Results and Discussion section as well as in Figure 4 and the Figure Legend (Figure 4B) have been amended to account for this correction. Additional r code for the meta-analysis can be found on the Open Science Framework: https://osf.io/x6g87/.
The corrected Figure 4 is shown here:
The originally published Figure 4 is also shown for reference:
The article has now been corrected.
- Received: January 3, 2018
- Accepted: January 3, 2018
- Version of Record published: January 8, 2018 (version 1)
© 2018, Aird et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.